<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05614817</url>
  </required_header>
  <id_info>
    <org_study_id>CBP-201-WW004</org_study_id>
    <secondary_id>2022-000999-19</secondary_id>
    <nct_id>NCT05614817</nct_id>
  </id_info>
  <brief_title>CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of CBP-201 Monotherapy in Patients With Moderate-To-Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Connect Biopharmaceuticals, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Connect Biopharmaceuticals, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, randomized, double-blinded, placebo-controlled trial in patients, ≥12&#xD;
      years of age who weigh ≥40 kg, and are diagnosed with moderate-to-severe AD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is comprised of a 2- to 6-week (Day-45 to Day 1) Screening Period, a 16-week&#xD;
      randomized, double-blind Treatment Period 1, a 36-week Treatment Period 2, and an 8-week&#xD;
      follow-up after the last dose of study drug. Therefore, participants will be enrolled in the&#xD;
      trial for a maximum of 66 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor Decision&#xD;
  </why_stopped>
  <start_date type="Anticipated">December 2022</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Global Assessment(IGA)(0-1)</measure>
    <time_frame>Baseline to Week16</time_frame>
    <description>The proportion of participants whose IGA score is 0-1 and decreased by ≥2 points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EASI-75</measure>
    <time_frame>Baseline at Week 16</time_frame>
    <description>The proportion of participants achieving EASI-75</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Pruritus Numerical Rating Scale（PP-NRS）(in the US)</measure>
    <time_frame>Baseline at Week16</time_frame>
    <description>The proportion of participants achieving an improvement (reduction) of ≥4 on Peak Pruritis numeric rating scale (PP-NRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment(IGA)(0-1) (outside of the US)</measure>
    <time_frame>Baseline at Week16</time_frame>
    <description>Proportion of participants achieving an IGA score of 0 or 1 and a 2-grade improvement in IGA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Pruritus Numerical Rating Scale（PP-NRS）(outside of the US)</measure>
    <time_frame>Baseline at Week16</time_frame>
    <description>Proportion of participants achieving an improvement (reduction) of ≥4 on PP-NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scoring Atopic Dermatitis(outside of the US)</measure>
    <time_frame>At Week16</time_frame>
    <description>Change in Scoring Atopic Dermatitis (SCORAD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index(outside of the US)</measure>
    <time_frame>Baseline at Week16</time_frame>
    <description>Change in Dermatology Life Quality Index (DLQI) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EASI-90</measure>
    <time_frame>Baseline at Week16</time_frame>
    <description>Proportion of participants achieving 90% reduction in EASI score</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>[Treatment Period 1]Group 1-Dose1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBP-201 600 mg (4 mL) SC on Day 1 (Week 0 visit) visit followed by 300 mg (2 mL) SC Q2W starting at Week 2 with the last dose at Week 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Treatment Period 1]Goup 2-Placebo1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (4 mL) SC on Day 0 (Week 0) visit followed by placebo (2 mL) SC Q2W starting at Week 2 with the last dose at Week 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Treatment Period 2] Group 1-Dose2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBP-201 300 mg SC Q2W starting at Week 16 with the last dose at Week 50 Treatment Period 2 (Group 1 Dose 1 responder pts that rerandomize to Dose 2, Dose 3, or PBO 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Treatment Period 2] Group 1-Dose3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBP-201 300 mg SC Q4W starting at Week 16, alternating with placebo SC Q4W starting at Week 18 with the last dose of CBP-201 at Week 48 and placebo at Week 50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Treatment Period 2] Group 1-Placebo2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Q2W SC starting at Week 16 with the last dose at Week 50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Treatment Period 2] Group 2-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBO 1 pts responders that continue PBO 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Treatment Period 2] Group 3-Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 and PBO 1 Non-responders, and Group 1 and 2 Non-responders that get open-label Dose 4 or 5 (LD 300 mg or 600 mg, biweekly 300 mg thereafter)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBP-201</intervention_name>
    <description>CBP-201 subcutaneous(SC) injection</description>
    <arm_group_label>[Treatment Period 1]Group 1-Dose1</arm_group_label>
    <arm_group_label>[Treatment Period 2] Group 1-Dose2</arm_group_label>
    <arm_group_label>[Treatment Period 2] Group 1-Dose3</arm_group_label>
    <arm_group_label>[Treatment Period 2] Group 3-Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>subcutaneous(SC) injection</description>
    <arm_group_label>[Treatment Period 1]Goup 2-Placebo1</arm_group_label>
    <arm_group_label>[Treatment Period 2] Group 1-Placebo2</arm_group_label>
    <arm_group_label>[Treatment Period 2] Group 2-Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
          -  Able to provide written informed consent or assent (as per local law).&#xD;
&#xD;
          -  Adults and adolescents of any sex or gender (12 years of age or older)&#xD;
&#xD;
          -  Body weight ≥ 40 kg at Screening&#xD;
&#xD;
          -  Diagnosis of chronic Atopic Dermatitis as defined according to American Academy of&#xD;
             Dermatology Consensus Criteria (Eichenfield 2014), present ≥ 3 year before Screening.&#xD;
&#xD;
        Atopic Dermatitis history with ALL the following disease activity criteria:&#xD;
&#xD;
          1. Involvement of ≥ 10% BSA at Screening and Baseline (Day 1).&#xD;
&#xD;
          2. An EASI score of ≥ 16 at Screening and Baseline (Day 1).&#xD;
&#xD;
          3. An IGA score of ≥ 3 at Screening and Baseline (Day 1).&#xD;
&#xD;
          4. Baseline weekly average of daily PP-NRS ≥ 4 at Baseline (Day1).&#xD;
&#xD;
             • Participant has applied a Sponsor approved emollient twice a day for at least 14&#xD;
             days before the Baseline Visit and agree to continue at least daily use during study&#xD;
             participation.&#xD;
&#xD;
             • Documented recent history (within 180 days before Screening) of inadequate response&#xD;
             to treatment with TCS or topical immunomodulator medication or for whom topical&#xD;
             treatments are otherwise medically inadvisable (e.g., important side effects or safety&#xD;
             risks).&#xD;
&#xD;
               -  Participants must agree to avoid the use of prohibited AD medications throughout&#xD;
                  the duration of the study.&#xD;
&#xD;
               -  In the opinion of the Investigator, participant is willing and able to comply&#xD;
                  with all study visits and study-related procedures.&#xD;
&#xD;
               -  Female patients of childbearing potential who are sexually active with a&#xD;
                  non-sterilized male partner should have a confirmed negative serum beta-human&#xD;
                  chorionic gonadotropin test at Visit 1 and agrees to use acceptable forms of&#xD;
                  birth control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        No current or past history of:&#xD;
&#xD;
          1. Other active skin diseases (e.g., psoriasis, lupus erythematosus etc.) or skin&#xD;
             infections (bacterial, fungal, or viral) that require systemic treatment within 4&#xD;
             weeks of Screening Visit or would interfere with the assessment of AD lesions.&#xD;
&#xD;
          2. History of recurrent herpes herpeticum in the prior 12 months or more than 2 episodes&#xD;
             of herpes herpeticum in past 2 years.&#xD;
&#xD;
          3. Non-skin related active infection requiring systemic treatment with parenteral&#xD;
             anti-infectives within 30 days or oral anti-infectives within 14 days before the&#xD;
             Baseline Visit (Visit 2).&#xD;
&#xD;
          4. Active human immunodeficiency virus (HIV) defined as a confirmed positive anti-HIV&#xD;
             antibody test.&#xD;
&#xD;
          5. Tuberculosis requiring treatment within the past 12 months before Screening. Note:&#xD;
             Evaluation of tuberculosis will be according to local guidelines as per standard of&#xD;
             care.&#xD;
&#xD;
          6. Active Hepatitis B virus (HBV) or hepatitis C virus (HCV).&#xD;
&#xD;
          7. HCV: HCV ribonucleic acid (RNA) detectable in any subject with anti-HCV antibody (HCV&#xD;
             Ab).&#xD;
&#xD;
             •&#xD;
&#xD;
        Participant may not have any of the following conditions:&#xD;
&#xD;
          1. Known primary immunodeficiency or immunocompromised&#xD;
&#xD;
          2. History of malignancy within 5 years before the Screening Visit except for completely&#xD;
             treated in situ carcinoma of the cervix or completely treated and resolved basal cell&#xD;
             carcinoma of the skin.&#xD;
&#xD;
          3. A helminth parasitic infection diagnosed within 6 months before Visit 1 that has not&#xD;
             been treated with or has failed to respond to standard of care therapy.&#xD;
&#xD;
          4. History of chronic alcohol or drug abuse including chronic use of cannabis (e.g.,&#xD;
             inhalation and/or consumption of marijuana more than once per week) within 12 months&#xD;
             before screening.&#xD;
&#xD;
          5. History of attempted suicide or is at significant risk of suicide.&#xD;
&#xD;
          6. History of anaphylaxis after administration of a biologic medication or vaccine.&#xD;
&#xD;
          7. History of hypersensitivity (including anaphylaxis) to an immunoglobulin product&#xD;
             (plasma-derived or recombinant, e.g., monoclonal antibody) or to any of the study drug&#xD;
             excipients [L-histidine, trehalose, or Tween (polysorbate) 80].&#xD;
&#xD;
          8. Any disorder, including, but not limited to cardiovascular, gastrointestinal, hepatic,&#xD;
             renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological,&#xD;
             psychiatric, or major physical impairment that is not stable in the opinion of the&#xD;
             Investigator and could: affect participant safety, alter the findings of the study or&#xD;
             the interpretation of study results, impede the participant's ability to complete the&#xD;
             entire duration of the study, or would require frequent bursts of systemic&#xD;
             corticosteroids.&#xD;
&#xD;
               -  Participant may not have Prior/Concomitant Therapy as follows:&#xD;
&#xD;
        a. Receipt of live (attenuated) vaccines within 30 days of Baseline (Day 1) NOTE: Receipt&#xD;
        of inactive/killed vaccines (e.g., influenza) or mRNA vaccines (e.g., COVID) are permitted&#xD;
        provided that they are not given within 5 days before/after any of the study visits.&#xD;
&#xD;
        b. Receipt or donation of any blood product in the 28 days before Baseline (Day 1).&#xD;
&#xD;
        NOTE: Patients who are not willing to abstain from donating blood and/or plasma from&#xD;
        Screening and for the 112 days after last dose of study drug should not be enrolled.&#xD;
&#xD;
        •&#xD;
&#xD;
        Participant is unable or unwilling to discontinue current prohibited AD treatments within&#xD;
        defined washout windows below and in prohibited medications Section 6.11, as applicable,&#xD;
        before Baseline (Visit 2):&#xD;
&#xD;
          1. Systemic JAK inhibitors including but not limited to ruxolitinib, tofacitinib,&#xD;
             baricitinib, upadacitinib, abrocitinib and filgotinib within 60 days&#xD;
&#xD;
          2. Lymphocyte depleting agents such as rituximab within 6 months or when lymphocyte&#xD;
             counts return to normal whichever is longer&#xD;
&#xD;
          3. Systemic therapy for AD including but not limited to corticosteroids, methotrexate,&#xD;
             cyclosporine, azathioprine, phosphodiesterase type 4 (PDE-4) inhibitors, or&#xD;
             mycophenolate mofetil within 4 weeks&#xD;
&#xD;
          4. Targeted biologic treatments (as listed in prohibited medication Section 6.11) within&#xD;
             5 half-lives (if known) or 12 weeks, whichever is longer&#xD;
&#xD;
          5. At any time prior to baseline, patient did not respond favorably to previous dupilumab&#xD;
             or other anti-IL4Rα or anti-IL-13 treatment (e.g., therapy failure, patient&#xD;
             experienced an adverse reaction to treatment)&#xD;
&#xD;
          6. Oral or parenteral traditional Chinese medicine within 4 weeks&#xD;
&#xD;
          7. Topical treatments other than the Sponsor permitted emollient, including but not&#xD;
             limited to TCS, TCI, PDE-4, antihistamines, or JAKi within 2 weeks&#xD;
&#xD;
          8. Phototherapy treatment, laser therapy, tanning booth, or extended sun exposure that&#xD;
             could affect disease severity or interfere with disease assessments within 4 weeks&#xD;
&#xD;
          9. Use of bleach baths in the prior 2 weeks&#xD;
&#xD;
         10. Topical anti-infectives within 2 weeks&#xD;
&#xD;
         11. Emollients only available by prescription within 2 weeks including those containing&#xD;
             ceramide, hyaluronic acid, urea, filaggrin, Vitamin D or Vitamin E, even if not&#xD;
             prescribed Prior/Concurrent Clinical Study Experience&#xD;
&#xD;
               -  Receipt of any experimental systemic medications in the 42 days before Baseline&#xD;
                  (Day 1), or 5 half-lives (if known), whichever is longer.&#xD;
&#xD;
               -  Previous enrollment in a CBP-201 treatment protocol and having received at least&#xD;
                  1 dose of active study drug.&#xD;
&#xD;
               -  Concurrent enrollment in another trial where the patient is receiving an&#xD;
                  experimental intervention.&#xD;
&#xD;
        Have the following laboratory abnormalities at Screening:&#xD;
&#xD;
          1. Hemoglobin ≤ 10 g/dL&#xD;
&#xD;
          2. Platelet count &lt; 100,000 cells/µL&#xD;
&#xD;
          3. Eosinophil count &gt; 1500 cells/ µL&#xD;
&#xD;
          4. Total creatine phosphokinase (CPK) &gt; 3 times the upper limit of the normal (ULN)&#xD;
&#xD;
          5. Alanine aminotransferase (ALT) ≥ 2.0xULN&#xD;
&#xD;
          6. Aspartate aminotransferase (AST) ≥ 2.0x ULN&#xD;
&#xD;
          7. Total Bilirubin ≥ 1.5x ULN (an isolated bilirubin &gt;1.5x ULN is acceptable if bilirubin&#xD;
             is fractionated, and the direct bilirubin is &lt; 35% or if the participant has known&#xD;
             Gilbert's Syndrome)&#xD;
&#xD;
          8. Alkaline Phosphatase &gt;2x ULN&#xD;
&#xD;
               -  Abnormal ECG at screening per investigator assessment.&#xD;
&#xD;
               -  Major surgery, requiring anesthesia, within 6 weeks before Baseline (Day 1), or&#xD;
                  planned in-patient surgery or hospitalization during study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzhou Connect</last_name>
    <role>Study Director</role>
    <affiliation>Suzhou Connect Biopharmaceuticals, Ltd.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 6, 2022</study_first_submitted>
  <study_first_submitted_qc>November 6, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>March 19, 2023</last_update_submitted>
  <last_update_submitted_qc>March 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eczema</keyword>
  <keyword>allergic dermatitis</keyword>
  <keyword>pruritis</keyword>
  <keyword>type 2 inflammation</keyword>
  <keyword>allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

